Eli Lilly threatens 340B hospitals with loss of discounts over claims data

Eli Lilly notified hospitals in the 340B drug discount program they must submit claims-level data for all 340B-purchased medicines or lose discounts starting October 1, 2026. The demand, referenced in signal 106, aims to enforce a federal appellate ruling allowing manufacturers to impose conditions on 340B contract pharmacies. Affected hospitals have a 90-day window to comply. Billing teams at 340B entities must coordinate with pharmacy and compliance staff immediately to audit data-sharing capabilities and assess the operational and financial impact of the mandate.